Core Viewpoint - The company plans to repurchase a portion of its public shares using its own funds and a special loan for share buyback, with a total investment of no less than 300 million yuan and no more than 600 million yuan [1] Group 1: Repurchase Details - The repurchase price will not exceed 53.5 yuan per share [1] - The repurchased shares are intended to maintain the company's value and protect shareholder rights [1] - The repurchase plan is within the board's authority and does not require shareholder meeting approval [1] Group 2: Financial Arrangements - The company has obtained a loan commitment letter from Shanghai Pudong Development Bank Tianjin Branch for a special loan not exceeding 500 million yuan, which is up to 90% of the total repurchase amount [1] - The loan term will not exceed 36 months [1] - The implementation period for the repurchase is within three months from the board's approval of the final repurchase plan [1]

Core Viewpoint - Company believes that its current stock price does not reflect its true value, prompting a new share buyback plan to enhance market value and protect shareholder interests [1] Group 1: Share Buyback Plan - Company plans to use its own funds and a special loan for share buyback, with a total amount between 300 million yuan (approximately 43 million USD) and 600 million yuan (approximately 86 million USD) [1] - The buyback price will not exceed 53.5 yuan per share [1] - Company has secured a loan commitment of up to 500 million yuan (approximately 72 million USD) from Shanghai Pudong Development Bank, covering up to 90% of the total buyback amount [1] Group 2: Market Context - As of October 13, the company's stock closed at 38.19 yuan per share, with a total market capitalization of 17.75 billion yuan (approximately 2.55 billion USD) [1] - The stock price has fallen below the company's latest net asset value per share, indicating a disconnect between market valuation and intrinsic value [1]

Core Viewpoint - Jiuan Medical (002432) plans to repurchase shares using its own funds and a special loan for share buyback, aiming to maintain company value and shareholder rights [1] Group 1: Share Buyback Details - The total amount for the share repurchase will not be less than 300 million and not exceed 600 million [1] - The repurchase price will not exceed 53.5 yuan per share [1] - The company has obtained a loan commitment letter from Shanghai Pudong Development Bank Tianjin Branch, with a special loan amount not exceeding 500 million, which is also capped at 90% of the total repurchase amount [1] Group 2: Loan Terms - The borrowing period for the special loan will not exceed 36 months [1]

太平洋证券股份有限公司 太平洋证券股份有限公司（以下简称"太平洋证券"或"保荐机构"）作 为天津九安医疗电子股份有限公司（以下简称"九安医疗"或"公司"）持续 督导工作的保荐机构，根据《上市公司募集资金监管规则》《深圳证券交易所 上市公司自律监管指引第 1 号——主板上市公司规范运作》和《深圳证券交易 所上市公司自律监管指引第 13 号——保荐业务》等相关规定，太平洋证券就公 司使用自有资金支付募投项目所需资金并以募集资金等额置换事项进行了核查， 现将核查情况及核查意见发表如下： 一、募集资金的基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准天津 九安医疗电子股份有限公司非公开发行股票的批复》（证监许可[2020]3324 号） 核准，公司 2020 年度非公开发行人民币普通股（A 股）股票 45,797,101 股，每 股面值为人民币 1.00 元，发行价为每股人民币 6.90 元，募集资金总额为人民币 315,999,996.90 元，扣除与发行有关的费用 6,630,702.76 元后，实际募集资金净 额为人民币 309,369,294.14 元。上述募集资金到位情况已经大华会计师 ...

Group 1 - The core point of the article is that Jiuan Medical (SZ 002432) announced a board meeting to discuss a share repurchase plan on October 13, 2025 [1] - Jiuan Medical's revenue composition for the first half of 2025 is as follows: 87.74% from medical devices, 6.57% from internet medical products and services, 5.03% from retail business, and 0.66% from other industries [1] - As of the report date, Jiuan Medical has a market capitalization of 17.8 billion yuan [1]

证券代码：002432 证券简称：九安医疗 公告编号：2025-076 天津九安医疗电子股份有限公司 关于使用自有资金支付募投项目所需资金 并以募集资金等额置换的公告 | 序号 | 项目名称 | 拟投入募集资金 金额（万元） | 已投入募集资金金额 （万元） | | --- | --- | --- | --- | | | 糖尿病照护服务及相关产品研发项目 | 24,490.00 | 20,246.96 | | 1 | 其中：共同照护中心扩展及系统研发升级项目 | 11,656.73 | 11,656.73 | | | 持续血糖监测系统（CGMS）研发项目 | 12,833.27 | 8,590.23 | | 2 | 智能化工厂改造项目 | 1,600.00 | 1,611.95 | | 3 | 新一代智能测温仪项目 | 1,151.08 | 1,151.08 | | 4 | 研发办公总部大楼建设及原厂区升级改造项目 | 6,123.64 | 15.42 | | | 合计 | 33,364.72 | 23,025.41 | 注：1、上述明细数与合计数的差额主要系四舍五入带来的尾差所致。 本公司及董事会全体成员保 ...

证券代码：002432 证券简称：九安医疗 公告编号：2025-075 天津九安医疗电子股份有限公司 关于回购公司股份方案 暨取得股票回购专项贷款承诺函的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 护公司价值及股东权益。 （二）回购股份符合相关条件的说明 公司本次回购股份符合《深圳证券交易所上市公司自律监管指引第 9 号——回购 股份》第十条规定的相关条件： 1、由于天津九安医疗电子股份有限公司(以下简称"公司")最近二级市场股票价格 已低于公司最近一期每股净资产，管理层认为当前二级市场股价不能反映公司价值。 近年来公司持续通过股份回购开展市值维护工作，并自 2025 年起有序推进、实施库存 股的注销工作。在此基础上，为进一步维护公司市场价值与股东权益，经综合考虑业 务发展前景、经营状况、财务状况、未来盈利能力等因素，公司拟使用自有资金及回 购专项贷款，通过集中竞价交易方式，开展新一期股份回购。公司拟使用自有资金及 回购专项贷资金通过二级市场以集中竞价交易的方式回购公司部分社会公众股份（以 下简称"本次回购"）。本次回购的资金总额不低于 ...

天津九安医疗电子股份有限公司(以下简称"公司"或"本公司")于2025年10月 10日以书面方式发出召开第六届监事会第二十一次会议的通知。会议于2025年10 月13日在公司会议室以现场表决方式召开。本次会议由公司监事长姚凯先生主持， 会议应参加的监事3名，实际参加的监事3名，会议的召集、召开与表决程序符合 《公司法》等法律法规及《公司章程》的规定。与会监事就会议议案进行了审议 及表决，通过了如下议案： 证券代码：002432 证券简称：九安医疗 公告编号：2025-074 天津九安医疗电子股份有限公司 第六届监事会第二十一次会议决议公告 本公司及监事会全体成员保证信息披露内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司监事会 2025年10月14日 一、以3票同意、0票反对、0票弃权的表决结果，审议并通过了《关于使用 自有资金支付募投项目所需资金并以募集资金等额置换的议案》 经审议，监事会认为公司募投项目预先使用自有资金支付募投项目部分款项， 再定期以募集资金等额置换的事项，履行了必要的决策程序，制定了相应的操作流 程，能够有效保证募投项目的正常开展，提高募集资金使 ...

证券代码：002432 证券简称：九安医疗 公告编号：2025-073 天津九安医疗电子股份有限公司 第六届董事会第二十七次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司(以下简称"公司"或"本公司")于2025年10月 10日以通讯方式发出召开第六届董事会第二十七次会议的通知，会议于2025年10 月13日在公司会议室以现场和通讯表决相结合方式召开。本次会议由公司董事长 刘毅先生主持，会议应参加的董事6名，实际参加的董事6名，全体监事、公司高 级管理人员列席了会议，符合《公司法》及《公司章程》的规定。根据《公司章 程》规定，与会董事就会议议案进行了审议、表决，审议通过如下议案： 一、逐项审议通过《关于公司回购股份方案的议案》 表决结果：6票同意，0票反对，0票弃权 （二）回购股份的方式及价格区间 1、回购股份的方式 本次回购股份将通过深圳证券交易所交易系统以集中竞价交易方式进行。 2、回购股份的价格区间 本次回购股份的价格为不超过人民币53.5元/股（含），该回购价格上限未超 过董事会通过回购股份决议前三十个交易日公 ...

Core Viewpoint - The company plans to initiate a new share buyback program using its own funds and a special loan, with a total buyback amount between 300 million yuan and 600 million yuan, and a maximum buyback price of 53.5 yuan per share [1] Group 1 - The total amount for the buyback will not be less than 300 million yuan and not exceed 600 million yuan [1] - The maximum buyback price is set at 53.5 yuan per share [1] - The repurchased shares will be used to maintain company value and shareholder rights, with plans to sell them within 12 months after the announcement of the buyback results [1] Group 2 - The company intends to sell the repurchased shares through centralized bidding within three years after the announcement [1] - If the shares are not sold within the legally stipulated timeframe, the unsold portion will be legally canceled [1]